Kyverna Therapeutics Inc [KYTX] stock is trading at $9.76, down -7.14%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KYTX shares have gain 11.93% over the last week, with a monthly amount glided 20.05%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on May 27, 2025, and kept the price target unchanged to $5. On October 10, 2024, UBS initiated with a Buy rating and assigned a price target of $13 on the stock. Rodman & Renshaw started tracking the stock assigning a Buy rating and suggested a price target of $16 on October 09, 2024. H.C. Wainwright initiated its recommendation with a Neutral and recommended $8 as its price target on July 03, 2024. Wells Fargo started tracking with a Overweight rating for this stock on March 04, 2024, and assigned it a price target of $44. In a note dated March 04, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $40 on this stock.
Kyverna Therapeutics Inc [KYTX] stock has fluctuated between $1.78 and $13.67 over the past year. Currently, Wall Street analysts expect the stock to reach $29.5 within the next 12 months. Kyverna Therapeutics Inc [NASDAQ: KYTX] shares were valued at $9.76 at the most recent close of the market. An investor can expect a potential return of 202.25% based on the average KYTX price forecast.
Analyzing the KYTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.86, Equity is -0.78 and Total Capital is -1.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Kyverna Therapeutics Inc’s Current Ratio is 5.16. As well, the Quick Ratio is 5.16, while the Cash Ratio is 1.01.
Transactions by insiders
Recent insider trading involved SEIDENBERG BETH C, Director, that happened on Dec 18 ’25 when 0.13 million shares were purchased. 10% Owner, Westlake BioPartners Opportuni completed a deal on Dec 18 ’25 to buy 0.13 million shares. Meanwhile, Chief Technology Officer Walker Karen Marie sold 23998.0 shares on Dec 15 ’25.
